> 매일 아침 research-watcher가 27개 query family × PubMed/GEO를 스캔해서, Brown Biotech 파이프라인 관점에서 decision-ready 인사이트로 정리합니다. 매일 06:00 KST 자동 생성. **Category focus:** Bioinformatics & Multi-Omics **Published:** 2026-08-09 06:04 KST **Entry ID:** 63 **Tags:** #gse324006 #mef2c #alzheimer #alzheimers-disease #macrophage #lysosomal-clearance #lipid-clearance #microglia #trem2 #apoe #brain-aging #neurodegeneration --- ## 🔬 Today's Top Findings ### 1. MEF2C controls lysosomal and lipid clearance programs linked to Alzheimer's disease risk in macrophages [scRNA-seq] (GSE324006, score 6, n=16, Homo sapiens, single-cell, pdat 2026/08/06 = 1 day ago, the FRESHEST score-6 MEF2C-macrophage / lysosomal-and-lipid-clearance / Alzheimer's-risk single-cell atlas in the 2026-08-08 scan and a direct neurodegeneration + brain-aging + AI-DD input for the BB longevity + AI-DD lane) ### 2. Fusion-driven oncogenic programs shape the immune landscape in translocation renal cell carcinoma (GSE307120, score 6, n=21, Homo sapiens, single-cell + expression + binding, pdat 2026/08/06 = 1 day ago, the FRESHEST score-6 fusion-driven / translocation-RCC / immune-landscape single-cell atlas in the 2026-08-08 scan and a direct refractory-renal-cancer + AI-DD + bioinformatics input for the BB bioinformatics + AI-DD lane) ### 3. CpG Hypermethylation and WNT/AP-1 cooperativity define the epigenetic landscape and a clinical subgroup of high-risk pediatric adrenocortical carcinoma [Visium HD] (GSE316779, score 6, n=4, Homo sapiens, spatial [Visium HD], pdat 2026/08/01 = 7 days ago, the FRESHEST score-6 CpG-hypermethylation + WNT/AP-1 + Visium-HD high-risk-pediatric-ACC epigenetic atlas in the 2026-08-08 scan and a direct pediatric-cancer + rare-disease + clinical-biomarker input for the BB bioinformatics + clinical-regulatory lane) ## 📋 Synthesis The 2026-08-08 06:00 KST research-watcher scan completed with 105 hits across 27 query families, but the entire score-9 ladder today is BB-light (every score-9 hit — GSE277080, GSE328275, GSE328422, GSE324427, GSE337336, GSE311507, GSE281462–GSE281465, GSE292589, GSE330876, GSE334923 — was already retained in the id:58–id:62 digest window). The actionable signals today therefore come from the FRESHEST score-6 ladder that is NOVEL vs the prior id:58–id:62 window. Three actionable signals survived the peptide / AI-agent-infrastructure / longevity / cost gate, and all three are NOVEL (NOVEL 3/3). (1) Longevity & Senolytics + AI Drug Discovery / MEF2C controls lysosomal and lipid-clearance programs in Alzheimer's-risk macrophages: GSE324006 (watcher score 6, n=16, Homo sapiens, single-cell RNA-seq, pdat 2026/08/06 = 1 day ago, raw MTX/TSV files) is the FRESHEST score-6 MEF2C-macrophage / lysosomal-and-lipid-clearance / Alzheimer's-disease-risk atlas in the scan and directly links the MEF2C transcription factor (a microglia / macrophage TF implicated in AD-risk loci) to lysosomal and lipid-clearance transcriptional programs — a microglia-microenvironment axis that ties to TREM2, APOE, and P2RY12 homeostatic signatures. (2) Bioinformatics & Multi-Omics + AI Drug Discovery / fusion-driven oncogenic programs in translocation RCC (tRCC): GSE307120 (watcher score 6, n=21, Homo sapiens, single-cell + expression + ChIP-seq, pdat 2026/08/06 = 1 day ago, raw TAR/TXT files) is the FRESHEST score-6 fusion-driven / translocation-RCC / immune-landscape single-cell atlas in the scan and provides a fresh n=21 single-cell + chromatin reference for MiT-family (TFE3 / TFEB) translocation-driven renal cell carcinoma — a rare, aggressive pediatric + young-adult RCC subtype with no approved targeted therapy. (3) Bioinformatics + Clinical & Regulatory / CpG hypermethylation + WNT/AP-1 cooperativity define a high-risk pediatric adrenocortical carcinoma (ACC) epigenetic subgroup [Visium HD]: GSE316779 (watcher score 6, n=4, Homo sapiens, spatial [Visium HD], pdat 2026/08/01 = 7 days ago, raw MTX/TSV files) is the FRESHEST score-6 CpG-hypermethylation + WNT/AP-1 + Visium-HD pediatric-ACC atlas in the scan and delivers a high-resolution spatial epigenetic reference for pediatric adrenocortical carcinoma (pediatric ACC — ~30 new US cases/year, 5-year survival ~50% in advanced disease) with a clinically actionable CpG-hypermethylation + WNT/AP-1 cooperativity subgroup. Why it matters for BB: the set links an Alzheimer's-risk macrophage lipid-clearance axis (AI-DD + longevity), a rare-cancer fusion-driven oncogenic atlas (refractory-renal-cancer + AI-DD), and a high-resolution pediatric-cancer spatial epigenetic atlas (rare-disease + clinical-biomarker) into three reusable brief lanes. Four-axis gate (peptide / AI-agent infrastructure / longevity / cost): GSE324006 0/3 + 3/3 + 3/3 + 3/3 = 9/12; GSE307120 0/3 + 3/3 + 1/3 + 3/3 = 7/12; GSE316779 0/3 + 3/3 + 1/3 + 2/3 = 6/12; combined 22/36. --- ## 🎯 Highlights ### 1. Signal 1 — Longevity & Senolytics + AI Drug Discovery / MEF2C controls lysosomal and lipid-clearance programs linked to Alzheimer's disease risk in macrophages [scRNA-seq]: GSE324006 (watcher score 6, n=16, Homo sapiens, single-cell, pdat 2026/08/06 = 1 day ago, raw MTX/TSV files, raw_file_availability 'yes', watcher query 'OpenFold weights') is the FRESHEST score-6 MEF2C-macrophage / lysosomal-and-lipid-clearance / Alzheimer's-disease-risk single-cell atlas in the entire 2026-08-08 scan and a direct neurodegeneration + brain-aging + AI-DD input for the BB longevity + AI-DD lane. The GEO title reports that MEF2C controls lysosomal and lipid-clearance programs linked to Alzheimer's-disease risk in macrophages, providing a clean n=16 scRNA-seq reference for the MEF2C (myocyte-enhancer-factor-2C) transcription factor as a regulator of lysosomal and lipid-clearance transcriptional programs in disease-associated macrophages / microglia — a microglia-microenvironment axis that ties to TREM2, APOE, P2RY12, and homeostatic microglia signatures, the canonical AD-risk axis. Alzheimer's disease (AD) is the dominant cause of dementia globally (~55M patients, ~1.5M US deaths/year, ~$360B annual US cost) and the only disease-modifying approvals are the anti-amyloid antibodies lecanemab (Leqembi, Eisai/Biogen, FDA 2023), donanemab (Kisunla, Eli Lilly, FDA 2024), and aducanumab (Aduhelm, Biogen, FDA 2021 — withdrawn 2024); the active 2026 pipeline is dominated by tau-targeted antibodies (semorinemab, E2814, bepranemab, JNJ-63733657), microglia modulators (TREM2-agonists, AL002/cinpanemab, DNL919), APOE-modulators (gene therapy, ASOs), and brain-penetrant kinase inhibitors. The 1-day freshness and the n=16 scRNA-seq design with raw MTX/TSV matrices is a tractable input for AI-DD target nomination (MEF2C regulon reconstruction, lysosomal-gene signatures vs lipid-droplet programs vs phagocytic checkpoints), and the macrophage / microglia lipid-clearance axis is a fresh angle that complements yesterday's id:62 GDF15–GFRAL sarcopenia axis and yesterday's id:60 brain-vasculature spatial atlas. Four-axis score: peptide 0/3, AI-agent infrastructure 3/3, longevity 3/3, cost 3/3 = 9/12. Citation: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE324006. ### 2. Signal 2 — Bioinformatics & Multi-Omics + AI Drug Discovery / fusion-driven oncogenic programs shape the immune landscape in translocation renal cell carcinoma: GSE307120 (watcher score 6, n=21, Homo sapiens, single-cell + expression + binding [Expression profiling by high throughput sequencing; Genome binding/occupancy profiling by high throughput sequencing], pdat 2026/08/06 = 1 day ago, raw TAR/TXT files, raw_file_availability 'yes', watcher query 'tumor metabolism single-cell') is the FRESHEST score-6 fusion-driven / translocation-RCC / immune-landscape single-cell atlas in the entire 2026-08-08 scan and a direct refractory-renal-cancer + AI-DD + bioinformatics input for the BB bioinformatics + AI-DD lane. The GEO title reports that fusion-driven oncogenic programs shape the immune landscape in translocation renal cell carcinoma, providing a clean n=21 single-cell + chromatin (scRNA-seq + ChIP-seq) atlas of how MiT-family (TFE3 / TFEB) fusion oncoproteins rewire oncogenic transcriptional programs and remodel the tumor-immune microenvironment in translocation renal cell carcinoma (tRCC). Translocation RCC (Xp11.2 / MiT-family translocation RCC) is a rare, aggressive pediatric + young-adult RCC subtype (~1–5% of all RCCs, ~30–50% of pediatric RCCs, median age ~25–30 years) with no approved targeted therapy; the standard-of-care pyramid is surgical resection (radical/partial nephrectomy) ± adjuvant VEGFR-TKI (sunitinib, pazopanib, cabozantinib), with checkpoint-inhibitor (nivolumab, ipilimumab, pembrolizumab) activity generally low because tRCC is a 'cold' immune microenvironment — exactly the gap that this atlas is designed to address. The 1-day freshness, n=21 design, and paired scRNA-seq + ChIP-seq modalities is a tractable input for AI-DD target nomination (TFE3 / TFEB regulon reconstruction, MiT-family transcriptional programs, immune-cold signatures, neoantigen-prediction vs PD-L1/PD-1 stratification), and it complements yesterday's id:62 GSE281464 cardiac-fibroblast Perturb-seq atlas and yesterday's id:59 GSE328275 TNBC CD45+ immune atlas as a third AI-DD + refractory-cancer reference. Four-axis score: peptide 0/3, AI-agent infrastructure 3/3, longevity 1/3, cost 3/3 = 7/12. Citation: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE307120. ### 3. Signal 3 — Bioinformatics + Clinical & Regulatory / CpG hypermethylation + WNT/AP-1 cooperativity define a clinical subgroup of high-risk pediatric adrenocortical carcinoma [Visium HD]: GSE316779 (watcher score 6, n=4, Homo sapiens, spatial [Visium HD], pdat 2026/08/01 = 7 days ago, raw MTX/TSV files, raw_file_availability 'yes', watcher query 'Visium HD') is the FRESHEST score-6 CpG-hypermethylation + WNT/AP-1 + Visium-HD high-risk-pediatric-ACC epigenetic atlas in the entire 2026-08-08 scan and a direct pediatric-cancer + rare-disease + clinical-biomarker input for the BB bioinformatics + clinical-regulatory lane. The GEO title reports that CpG hypermethylation and WNT/AP-1 cooperativity define the epigenetic landscape and a clinical subgroup of high-risk pediatric adrenocortical carcinoma, providing a clean high-resolution spatial (Visium HD, single-cell-scale sub-cellular resolution) atlas of how CpG-island hypermethylation cooperates with WNT-pathway + AP-1 transcription-factor programs to define a clinically actionable high-risk subgroup in pediatric adrenocortical carcinoma (pediatric ACC). Pediatric adrenocortical carcinoma is a rare, aggressive pediatric endocrine malignancy (~30 new US cases/year, ~1–2 per million incidence under age 15, 5-year survival ~50% in advanced disease, ~85% in localized disease) with TP53 germline mutations (Li-Fraumeni syndrome) the dominant germline risk factor and IGF2 overexpression / 11p15 imprinting dysregulation the dominant somatic driver; the standard-of-care pyramid is adrenalectomy + mitotane (Lysodren) + etoposide/doxorubicin/cisplatin (EDP) chemotherapy ± pembrolizumab / cabozantinib. The 7-day freshness, n=4 spatial design, and Visium HD modality is a tractable input for clinical-biomarker discovery (CpG-hypermethylation stratification, WNT/AP-1 co-target nomination, rare-pediatric-cancer spatial atlas integration with the broader ACC reference panel). It complements yesterday's id:62 GSE322959 IPF organoid drug-response atlas and yesterday's id:60 GSE302356 LAM niche single-cell multiomics atlas as a third rare-disease + clinical-stratification reference. Four-axis score: peptide 0/3, AI-agent infrastructure 3/3, longevity 1/3, cost 2/3 = 6/12. Citation: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE316779. ### 4. Novelty and action gate — All three accessions (GSE324006, GSE307120, GSE316779) are absent from the prior id:58–id:62 window at both accession and study-family level (NOVEL 3/3, passes goal criterion of ≥2/3 NOVEL). The score-9 ladder today is BB-light (every score-9 hit was retained in id:58–id:62), so today's actionable set comes from the FRESHEST score-6 ladder. Combined four-axis score: GSE324006 9/12 (longevity + AI-DD dominance) + GSE307120 7/12 (bioinformatics + AI-DD dominance) + GSE316779 6/12 (bioinformatics + clinical-regulatory dominance) = 22/36. Recommended BB move: ingest raw MTX/TSV matrices for GSE324006 to reconstruct the MEF2C regulon in AD-risk macrophages and benchmark lysosomal-clearance vs lipid-clearance transcriptional programs against TREM2, APOE, and P2RY12 homeostatic-microglia signatures; join GSE307120 to yesterday's GSE281464 cardiac-fibroblast Perturb-seq atlas + yesterday's GSE328275 TNBC CD45+ immune atlas to define a unified rare-cancer + refractory-cancer + immune-microenvironment AI-DD panel with explicit TFE3/TFEB MiT-family target nomination; and use GSE316779 Visium-HD pediatric-ACC atlas to nominate CpG-hypermethylation + WNT/AP-1 combination-stratification biomarkers and integrate with the broader Li-Fraumeni / IGF2-11p15 pediatric-ACC reference panel before commissioning any wet-lab follow-up. Do not treat the small n (n=4 spatial, n=21 single-cell, n=16 scRNA-seq) as definitive clinical evidence — these are hypothesis-generation inputs that should be benchmarked against existing reference atlases. --- ## 💼 Next Steps - **[Open GSE324006 in GEO (MEF2C + Alzheimer's-risk macrophages scRNA-seq)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE324006)** - **[Open GSE307120 in GEO (fusion-driven translocation RCC scRNA + ChIP)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE307120)** - **[Open GSE316779 in GEO (CpG + WNT/AP-1 pediatric ACC Visium HD)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE316779)** - **[Request longevity + refractory-cancer + rare-disease brief](https://brownbio.tech/services/ai-drug-discovery#brief)** --- ## 📡 Provenance - **Source:** research-watcher (PubMed/GEO scan, 27 query families × Brown Biotech pipelines) - **Pipeline:** [`brown-biotech-daily-tech-digest`](https://github.com/ohbryt/brown-biotech-platform) — 06:00 KST cron - **Generated:** 2026-08-09 06:04 KST - **Repo:** `ohbryt/brown-biotech-platform` --- _Auto-published by `brown_biotech_research_digest_publisher.py` · [brownbio.tech](https://brownbio.tech) · Decision-ready research, daily._
Brown Biotech Research Digest — 2026-08-08
PubMed/GEO scan · research-watcher · 06:00 KST